Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 10:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 168 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo/escitalopram Clear all
Completed Phase 3 Interventional Results available

Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

NCT01838681
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, Brexpiprazole, ADT
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,986 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
8
States / cities
Little Rock, Arkansas • Cerritos, California • Temecula, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 7, 2026, 10:41 PM EDT
Recruiting Phase 2 Interventional

Escitalopram and Language Intervention for Subacute Aphasia

NCT03843463
View directory record Official record
Conditions
Aphasia, Stroke
Interventions
Escitalopram 10mg, Placebo, Computer-delivered naming treatment
Drug · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Baltimore, Maryland • Charleston, South Carolina • Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 7, 2026, 10:41 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms

NCT01189812
View directory record Official record
Conditions
Major Depressive Disorder, Dysthymia, Depression Not Otherwise Specified, Borderline Personality Disorder
Interventions
Lithium Carbonate, Placebo, Citalopram
Drug
Lead sponsor
Columbia Northwest Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
San Diego, California • Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Aug 24, 2011 · Synced Oct 7, 2026, 10:41 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Neurobiology of Serotonin and Addiction

NCT00732901
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 55 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2019 · Synced Oct 7, 2026, 10:41 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder

NCT00252330
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SR58611A
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
476 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 12, 2009 · Synced Oct 7, 2026, 10:41 PM EDT
Completed Not applicable Interventional

Antidepressant Treatment in Older Adults With Schizophrenia

NCT00047450
View directory record Official record
Conditions
Schizophrenia
Interventions
Citalopram (Celexa), Placebo
Drug
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
40 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
2
States / cities
San Diego, California • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 9, 2013 · Synced Oct 7, 2026, 10:41 PM EDT
Recruiting Phase 2 Interventional

Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression

NCT06591091
View directory record Official record
Conditions
Depression
Interventions
Clemastine Fumarate, Placebo
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
60 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 7, 2026, 10:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Antidepressant Medication Plus Donepezil for Treating Late-life Depression

NCT00177671
View directory record Official record
Conditions
Depression, Dementia
Interventions
Escitalopram, Donepezil, Venlafaxine, Placebo, Duloxetine
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
65 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Oct 7, 2026, 10:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Effects of Duloxetine on Norepinephrine

NCT00414323
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Duloxetine, Escitalopram, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
2
States / cities
Glendale, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2007 · Synced Oct 7, 2026, 10:41 PM EDT
Completed Phase 3 Interventional

An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder

NCT00415142
View directory record Official record
Conditions
Depressive Disorder
Interventions
saredutant (SR48968), placebo, escitalopram
Drug
Lead sponsor
Sanofi
Industry
Eligibility
60 Years to 64 Years
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 24, 2016 · Synced Oct 7, 2026, 10:41 PM EDT
Completed Phase 4 Interventional Results available

Brain Aging and Treatment Response in Geriatric Depression

NCT01902004
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Depression
Interventions
Escitalopram, Memantine, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
60 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 7, 2026, 10:41 PM EDT
Terminated Not applicable Interventional Results available

Ramelteon for Sleep Initiation Insomnia in Individuals With Panic Disorder Who Are Also on Escitalopram for Anxiety

NCT00746239
View directory record Official record
Conditions
Panic Disorder, Insomnia
Interventions
Placebo and Escitalopram, Ramelteon and Escitalopram
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 7, 2026, 10:41 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02418585
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Orange, California • San Rafael, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 7, 2026, 10:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Brain Effects of Escitalopram and Citalopram Using fMRI

NCT00825825
View directory record Official record
Conditions
Antidepressant Activity in Healthy Volunteers
Interventions
Escitalopram, Citalopram, Placebo
Drug
Lead sponsor
Michael Henry, MD
Other
Eligibility
21 Years to 50 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 14, 2015 · Synced Oct 7, 2026, 10:41 PM EDT
Completed Phase 2 Interventional Results available

A Controlled Trial of Serotonin Reuptake Inhibitors Added to Stimulant Medication in Youth With Severe Mood Dysregulation

NCT00794040
View directory record Official record
Conditions
Mood Disorder, Mental Disorder Diagnosed in Childhood, Attention Deficit and Disruptive Behavior Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Add-on citalopram following optimized methylphenidate, Add-on placebo following optimized methylphenidate
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
7 Years to 17 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 7, 2026, 10:41 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Methylphenidate in Improving Cognition and Function in Older Adults With Depression

NCT00602290
View directory record Official record
Conditions
Depression
Interventions
Citalopram, Methylphenidate (MPH), Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
60 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Oct 7, 2026, 10:41 PM EDT
Completed Phase 4 Interventional Results available

DECIFER: Depression and Citalopram In First Episode Recovery

NCT01041274
View directory record Official record
Conditions
Schizophrenia, Schizophreniform Disorder
Interventions
Citalopram, Placebo, Psychoeducation, Cognitive Behavioral Therapy (CBT), Functional Magnetic Resonance Imaging (fMRI)
Drug · Behavioral · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years to 40 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 7, 2026, 10:41 PM EDT
Completed Not applicable Interventional Results available

Antidepressant Treatment Plus Cognitive Behavioral Therapy for Generalized Anxiety Disorder in Older Adults

NCT00601965
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Escitalopram, Placebo, Cognitive behavioral therapy (CBT)
Drug · Behavioral
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
60 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
San Diego, California • St Louis, Missouri • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Oct 7, 2026, 10:41 PM EDT
Completed Phase 3 Interventional Results available

Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder

NCT00149799
View directory record Official record
Conditions
Anxiety Disorders, Somatoform Disorders
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Oct 7, 2026, 10:41 PM EDT
Completed Phase 3 Interventional Results available

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression

NCT02493868
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
53
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 7, 2026, 10:41 PM EDT
Completed Phase 4 Interventional Results available

Connectivity Affecting the Antidepressant REsponse Study

NCT02332291
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Bupropion XL
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
60 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Oct 7, 2026, 10:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Escitalopram Effects on CSF Amyloid Beta

NCT02161458
View directory record Official record
Conditions
Amyloid Beta Protein
Interventions
Escitalopram 20mg for 2 weeks, Escitalopram 20mg for 8 weeks, Escitalopram 30mg for 8 weeks, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
60 Years to 85 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
2
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Oct 7, 2026, 10:41 PM EDT
Withdrawn Phase 1 Interventional

Enhancing Processing Speed and Executive Functioning in Depressed Older Adults With Computerized Cognitive Training

NCT04836533
View directory record Official record
Conditions
Depression in Old Age, Depression
Interventions
Experimental: Computerized Cognitive Training, Experimental: Open-label antidepressant treatment, Active Comparator: Solitaire Training, Placebo Comparator: Placebo-controlled antidepressant treatment
Other · Drug
Lead sponsor
Queens College, The City University of New York
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Oct 7, 2026, 10:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Characteristics of Sleep Patterns in Young Adults With and Without Insomnia

NCT00177216
View directory record Official record
Conditions
Sleep Disorders
Interventions
Zolpidem, Escitalopram, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
20 Years to 50 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 30, 2016 · Synced Oct 7, 2026, 10:41 PM EDT